New hope for myelofibrosis patients: experimental pill targets resistant disease
Disease control
Recruiting now
This early-stage study tests an experimental oral drug, AJ1-11095, in about 76 adults with myelofibrosis (a type of bone marrow cancer) whose disease has stopped responding to standard JAK2 inhibitor therapy. The main goals are to check the drug's safety, find the best dose, and …
Phase: PHASE1 • Sponsor: Ajax Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC